ACADIA Pharmaceuticals Inc. Stock News

Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Russell 2000 Index is pulling back today after hitting a major resistance level yesterday.

Analysts fell to the sidelines weighing in on Vertex Pharmaceuticals (VRTX), United Therapeutics (UTHR) and Alkermes (ALKS) with neutral ratings,

Columbus Circle Investors boosted its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 162.9% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Com

ACADIA Pharmaceuticals (NASDAQ:ACAD) will be releasing its earnings data after the market closes on Thursday, May 7th. Analysts expect ACADIA Pharmaceuticals to post earnings of ($0.45) per share for

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on LivaNova (LIVN), Crispr Therapeutics AG (CRSP) and

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on LivaNova (LIVN

In a report released today, Alan Carr from Needham assigned a Hold rating to Gilead Sciences (GILD). The company's shares closed last Wednesday at $83.05,

In a report released today, Alan Carr from Needham assigned a Hold rating to Gilead Sciences (GILD – Research Report).

The Michael J. Fox Foundation for Parkinson's Research (MJFF) has released a new video, "Together, We Can Solve the Parkinson's Puzzle," to illustrate the role each individual within a family and comm

Aging seniors have been put firmly in the crosshairs of the novel coronavirus. These 10 stocks to buy will benefit from this brutal reality.

Oppenheimer analyst Jay Olson maintained a Buy rating on Neurocrine (NBIX) today and set a price target of $130.00. The company's shares closed last